Medtronic Raises Fiscal 2027 Forecasts Amid Heart Device Surge

Medtronic has increased its fiscal 2027 revenue and profit forecasts, attributing the boost to a surge in demand for its heart devices used in complex cardiovascular procedures. This comes as the company benefits from the broader adoption of new medical technologies and a robust demand for surgeries.

Strategic Investments in Heart and Robotic Technologies

In a strategic move, Medtronic announced an $80 million investment in Pi-Cardia, a heart-valve repair device manufacturer, with an option to acquire the company for $210 million. Additionally, Medtronic has invested $700 million in Cornerstone Robotics, securing distribution rights for a robotic surgical device in select markets outside the United States. According to CEO Geoff Martha, these investments align with the company’s focus on high-growth segments within the medtech industry.

Martha highlighted the underpenetration of soft tissue robotic surgery in emerging markets, noting that Cornerstone's Sentire device complements Medtronic's existing Hugo surgical system. He emphasized the company's steady M&A activity, prioritizing segments with large patient pools and significant growth potential.

Financial Performance and Outlook

Medtronic raised the lower end of its fiscal 2027 adjusted per-share profit forecast to $5.94, up from $5.90, while maintaining the upper end at $6. The company now anticipates annual organic revenue growth between 7.25% and 7.75%, compared to the previous projection of 6.75% to 7.25%.

The company's cardiovascular segment reported a 19.5% increase in quarterly sales, reaching $3.93 billion. This growth was largely driven by an 88% increase in its pulsed field ablation portfolio, utilized for treating irregular heart rhythms. Medtronic reported an adjusted quarterly per-share profit of $1.45 on revenue of $9.76 billion, surpassing estimates of $1.39 and $9.55 billion, respectively, according to LSEG-compiled data.

Thierry Pieton, Medtronic's finance chief, noted that the company received tariff refunds that nearly offset the duties paid during the quarter. However, these refunds have not been factored into future forecasts.

Market Confidence and Expansion

CEO Martha expressed confidence in the company's performance, citing not only the strength of the recent quarter but also the broad-based contributions from newer growth platforms. Medtronic’s strategic investments and robust product demand underscore its commitment to expanding its foothold in the medtech industry.